Oral N-acetylglucosamine in Crohn's Disease
In plain words A Phase 2 study of N-Acetyl Glucosamine in people 18 to 80, run by Johns Hopkins University. It plans to enroll about 40 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 80. Conditions: Crohns Disease.
- Age 18 and 80 years of age
- Diagnosis of CD involving ileum (L1) or ileocolonic disease (L3) of any disease behavior
- On stable dosing of any CD therapy for >/= 8 weeks (inclusive of biologics, small molecules, immunomodulators)
- CDAI <450
7 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
N-Acetylglucosamine (GlcNAc)
Registered summary
Protein glycosylation is a critical post-translational modification that regulates protein trafficking and protein-protein interactions impacting a host of physiological processes. There is a growing appreciation of glycosylation defects in chronic human diseases, including Crohns disease. Crohns disease (CD), and the related condition of ulcerative colitis, are chronic inflammatory bowel diseases (IBD) that impact 3.1 million Americans. The full summary is on the listing.
Where, as registered
1 US site in 1 state.